×
About 88,083 results

Clinical Edge Journal Scan Commentary: RA December 2021
https://www.mdedge.com/rheumatology/article/249460/rheumatoid-arthritis/clinical-edge-journal-scan-commentary-ra-december
Arundathi Jayatilleke, MD

Dec 4th, 2021 - Arundathi Jayatilleke, MD Many people with rheumatoid arthritis (RA) have concomitant hand osteoarthritis (OA). This Swiss cohort study by Lechtenboehmer et al 1 using a longitudinal registry of RA patients examined characteristics of RA patients who had progression of radiographic hand OA.

Clinical Edge Journal Scan Commentary: PsA December 2021
https://www.mdedge.com/rheumatology/article/249458/psoriatic-arthritis/clinical-edge-journal-scan-commentary-psa-december
Vinod Chandran, MBBS, MD, DM, PhD

Dec 4th, 2021 - Vinod Chandran, MBBS, MD, DM, PhD Research published in November has provided us with insights on the impact of psoriatic arthritis (PsA) as well as treatment outcomes. Although PsA often affects women of child-bearing age, data on pregnancy outcomes in PsA is scarce.

Ribociclib/Everolimus Elicits Responses in Dedifferentiated Liposarcoma
https://www.onclive.com/view/ribociclib-everolimus-elicits-responses-in-dedifferentiated-liposarcoma

Dec 4th, 2021 - The combination of ribociclib (Kisqali) and everolimus (Afinitor) elicits responses in patients with advanced dedifferentiated liposarcoma (DDLPS) and offers a tolerable safety profile, according to Margaret von Mehren, MD, who added that these responses have not previously been seen in this patient population with CDK4 inhibitors. The phase 2 SAR-096 trial (NCT03114527) met its primary end ...

Dr. Bupathi on the Evolving Treatment Landscape of Bladder Cancer
https://www.onclive.com/view/dr-bupathi-on-the-evolving-treatment-landscape-of-bladder-cancer

Dec 3rd, 2021 - Manojkumar Bupathi, MD, MS, medical oncologist, Rocky Mountain Cancer Centers, discusses the evolving treatment landscape of bladder cancer. Although unmet needs exist in bladder cancer, the integration of maintenance therapy has improved survival outcomes for patients, Bupathi says. However, it remains unknown why some patients do not derive sufficient responses to available therapy. As suc...

High Altitudes Mess With CPR Skills in Trained EMS Personnel
https://www.medpagetoday.com/emergencymedicine/emergencymedicine/96002

Dec 3rd, 2021 - High altitude hurt the quality of chest compressions from trained rescuers without them realizing it, experiments showed. At simulated altitudes of 200, 3,000, or 5,000 meters in a hypobaric chamber, helicopter EMS personnel started out with optimal chest compressions on manikins, but gradually lost both the depth in their compressions and the proper pacing of effective compressions over time, ...

Increasing Seasonal Influenza A (H3N2) Activity, Especially Among Young Adults and in College and University Settings, During SARS-CoV-2 Co-Circulation - Health Alert Network (HAN) No. 458
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/454626

The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Advisory about increased influenza A(H3N2) activity that could mark the beginning of the 2021-2022 influenza season.

Year in Review: Respiratory Syncytial Virus
https://www.medpagetoday.com/infectiousdisease/uritheflu/95993

Dec 3rd, 2021 - Progress continued on a vaccine against respiratory syncytial virus (RSV) for older adults, while the country experienced a resurgence in infections among young children this year that caused the CDC to issue a Health Advisory on the illness. Vaccine Development in Older Adults Continues to Accelerate Janssen's adenoviral vector vaccine against RSV in older adults was safe and effective, partic...

Systemic Lupus Erythematosus Updates at ACR 2021: Novel Agents and Combination Regimens
https://www.mdedge.com/rheumatology/article/249175/systemic-lupus-erythematosus-updates-acr-2021-novel-agents-and
Joan Merrill, MD

Dec 3rd, 2021 - Dr Joan Merrill, of the Oklahoma Medical Research Foundation in Oklahoma City, reviews updates on several treatment options for systemic lupus erythematosus that were presented at the 2021 ACR Convergence. Dr Merrill begins by sharing data from a phase 2 study in which she and her colleagues investigated the efficacy and safety data for iberdomide.

De-Escalated Approaches Continue to Show Benefit in HER2+ Breast Cancer
https://www.onclive.com/view/de-escalated-approaches-continue-to-show-benefit-in-her2-breast-cancer

Dec 2nd, 2021 - The shift away from chemotherapy as a standard treatment for patients with HER2-positive breast has continued with the incorporation of de-escalated therapies into the treatment paradigm, according to Deborah L. Toppmeyer, MD. Allowing patients to avoid potential adverse events associated with chemotherapy has been a key benefit of expanded treatment options, Toppmeyer said. She added that the...

Bevacizumab Add-On No Help in Progressive EGFR-Mutant Lung Cancer
https://www.medpagetoday.com/hematologyoncology/lungcancer/95985

Dec 2nd, 2021 - Adding the angiogenesis inhibitor bevacizumab (Avastin) to osimertinib (Tagrisso) failed to slow progression of advanced EGFR-mutant non-small-cell lung cancer (NSCLC) that had progressed on prior anti-EGFR therapy, a randomized trial showed. Median progression-free survival (PFS) increased from 12.3 months with osimertinib alone to 15.4 months with the combination, but the difference did not a...

Did Trump Have COVID at First Debate? Cats Busted for Misinfo; Myeloma Drug Yanked
https://www.medpagetoday.com/infectiousdisease/covid19/95968

Dec 2nd, 2021 - Note that some links may require registration or subscription. Donald Trump tested positive for COVID-19 days before the first presidential debate against Joe Biden, according to his chief of staff at the time and other former aids; Trump denounced the claims as "fake news." (Washington Post) In order to track travel-related Omicron cases, the CDC ordered airlines to share data on passengers ar...

Treatment Sequencing Could Change With Complementary Combinations and CAR T Options in B-ALL
https://www.onclive.com/view/treatment-sequencing-could-change-with-complementary-combinations-and-car-t-options-in-b-all

Dec 1st, 2021 - Significant progress with rapidly evolving therapies, including blinatumomab (Blincyto), inotuzumab ozogamicin (Besponsa), and chimeric antigen receptor (CAR) T-cell therapy, has been made to extend the median overall survival (OS) and improve outcomes for patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). Antibody-based therapies and CAR T-cell therapies are not mut...

Therapeutic Frontiers for Relapsed/Refractory Multiple Myeloma Expand With CAR T and Bispecific Antibodies
https://www.onclive.com/view/therapeutic-frontiers-for-relapsed-refractory-multiple-myeloma-expand-with-car-t-and-bispecific-antibodies

Dec 1st, 2021 - Multiple Myeloma is a clonal plasma cell neoplasm characterized by bone lesions, renal impairment, cytopenias, and immunodeficiency. Despite significant therapeutic advancements in the past 2 decades that have resulted in improved survival, myeloma remains an incurable disease. The immune environment in which the cancer cells thrive is known to be a key player in the evolution of monoclonal gam...

New Online Tool Details COVID Infection Risks by Various Routes
https://www.medpagetoday.com/infectiousdisease/covid19/95961

Dec 1st, 2021 - A web-based system developed by British academic researchers was unveiled Wednesday that illustrates, in simple graphical form, how much various mitigation measures reduce the risk of SARS-CoV-2 transmission in different situations. The system depicts two people, one infected on the left, and one uninfected on the right. Connecting them are shaded arrows representing different potential transmi...

FluView: Situation Update, Summary of Weekly Report
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/132566

FluView Activity Update (Key Flu Indicators)

Retifanlimab Shows Promising Antitumor Activity in Advanced Endometrial Cancer
https://www.onclive.com/view/retifanlimab-shows-promising-antitumor-activity-in-advanced-endometrial-cancer

Dec 1st, 2021 - Retifanlimab (INCMGA 0012) demonstrated encouraging antitumor activity with favorable tolerability in patients with recurrent microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer, according to data from the phase 1 POD1UM-101 trial (NCT03059823), presented during the 2021 SITC Annual Meeting.1 At a median follow-up of 8.4 months (range, 1.9-28.3), the ...

Certolizumab seems effective as monotherapy in RA patients with failure to csDMARDs
https://www.mdedge.com/rheumatology/article/249283/rheumatoid-arthritis/certolizumab-seems-effective-monotherapy-ra

Dec 1st, 2021 - Key clinical point: Certolizumab (CTZ) monotherapy seemed as effective as combination therapy with methotrexate (MTX) or leflunomide (LFN) or MTX+LFN in patients with rheumatoid arthritis (RA) who failed previous conventional synthetic disease-modifying antirheumatic drugs (csDMARD) therapy. Major finding: Overall, 63% of patients were in remission or showed low disease activity (LDA) within 3.

Alvocidib followed by cytarabine and mitoxantrone shows clinical activity in MCL-1-dependent R/R AML
https://www.mdedge.com/hematology-oncology/article/249262/aml/alvocidib-followed-cytarabine-and-mitoxantrone-shows-clinical

Dec 1st, 2021 - Key clinical point: Alvocidib followed by cytarabine and mitoxantrone (ACM) was clinically active and well tolerated in patients with myeloid cell leukemia-1 (MCL-1)-dependent relapsed/refractory (R/R) acute myeloid leukemia (AML). Major finding: The rates of composite complete remission after 1 cycle of ACM therapy were 47%, 21%, 64%, and 52% in patients with R/R AML with MCL-1 <15%, 15% to <3.

TNF-α inhibitor remains a promising therapy for nail psoriasis and concomitant PsA
https://www.mdedge.com/dermatology/article/249253/psoriatic-arthritis/tnf-inhibitor-remains-promising-therapy-nail

Dec 1st, 2021 - Key clinical point: Tumor necrosis factor (TNF)- α inhibitors effectively improved skin, nail, and joint symptoms and quality of life (QoL) in patients with nail psoriasis and concomitant psoriatic arthritis (PsA). Major finding: During the first 3 months, nail psoriasis improved significantly along with improvements in the mean number of swollen joints (SJ), which reduced from 6.

Upadacitinib improves PRO in PsA patients with inadequate response to non-bDMARD
https://www.mdedge.com/dermatology/article/249252/psoriatic-arthritis/upadacitinib-improves-pro-psa-patients-inadequate

Dec 1st, 2021 - Key clinical point: Upadacitinib led to early and sustained clinically meaningful improvements in patient-reported outcomes (PRO) in patients with psoriatic arthritis (PsA) having an inadequate response to nonbiologic disease-modifying antirheumatic drugs (non-bDMARD). Major finding: A greater proportion of patients treated with 15 and 30 mg upadacitinib vs.